2021

Salah-Eddin Al-Batran, Ralf-Dieter Hofheinz, Alexander Reichart, Claudia Pauligk , Caroline Schönherr, Rudolf Schlag, Gabriele Siegler, Steffen Dörfel, Michael Koenigsmann, Mark-Oliver Zahn, Jörg Schubert, Ali Aldaoud, Heinz-Gert Höffkes, Holger Schulz, Lars Hahn, Jens Uhlig, Wolfgang Blau, Martina Stauch, Jörg Weniger, Martin Wolf, Lutz Jacobasch, Stephan Bildat, Jürgen Wehmeyer, Nils Homann, Jörg Trojan, Oliver Waidmann, Thomas Fietz, Hans-Peter Feustel, Matthias Groschek, Jan Wierecky, Karin Waibel, Stefan Mahlmann, Uwe Schwindel, Uwe Peters, Gunter Schuch, Daniel Pink, Henning Eschenburg, Marcus-A Wörns, Hans-Detlev Harich, Ludwig Fischer von Weikersthal, Klaus-Ulrich Däßler, Dirk M Behringer, Helmut Messmann, Albrecht Kretzschmar, Eike Gallmeier, Helmut Forstbauer, Volker Kunzmann, Jens Papke, Petra Büchner-Steudel, Ursula Vehling-Kaiser, Christoph Springfeld, Arndt Vogel, Thomas J Ettrich, Marina Schaaf, Gerrit Zur Hausen, Thorsten Oliver Götze, Arbeitsgemeinschaft Internistische Onkologie (AIO). Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. Int J Cancer. 2021 Mar 15;148(6):1478-1488. doi: 10.1002/ijc.33336. Epub 2020 Oct 23.

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Edin Al-Batran, Tobias Heintges, Christoph Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Markus Moehler , Werner Scheithauer, Swantje Held, Lisa Miller-Phillips, Dominik Paul Modest, Andreas Jung, Thomas Kirchner, Sebastian Stintzing. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9. Epub 2020 Nov 6.

Zev A Wainberg, Charles S Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter C Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia , Joseph Chao. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score {greater than or equal to}10.  Clin Cancer Res. 2021 Jan 14;clincanres.2980.2020. doi: 10.1158/1078-0432.CCR-20-2980. Online ahead of print.

2020

Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Peter Thuss-Patience, Hans-Georg Kopp, Tobias Dechow, Arndt Vogel, Kim Barbara Luley, Daniel Pink, Michael Stahl, Frank Kullmann, Holger Hebart, Jens Siveke, Matthias Egger, Nils Homann, Stephan Probst, Thorsten Oliver Goetze, Salah-Eddin Al-Batran. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int J Cancer. 2020 Nov 1;147(9):2493-2502. doi: 10.1002/ijc.33025. Epub 2020 May 7.

Sylvie Lorenzen, Alexander Biederstädt, Ulrich Ronellenfitsch, Christoph Reißfelder, Stefan Mönig, Frederik Wenz, Claudia Pauligk, Martin Walker, Salah-Eddin Al-Batran, Bernhard Haller, Ralf-Dieter Hofheinz. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer.2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.

Salah-Eddin Al-Batran, Enno Moorahrend, Christoph Maintz, Thorsten O Goetze, Dirk Hempel, Peter Thuss-Patience, Vincent E Gaillard, Susanna Hegewisch-Becker. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Oncologist. 2020 Aug;25(8):e1181-e1187. doi: 10.1634/theoncologist.2020-0109. Epub 2020 Jun 4.

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Jochen Schütte, Silke Cameron, Peter Hohenberger, Philipp J Jost, Salah-Eddin Al-Batran, Lars H Lindner, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Raija Kallio, Panu Jaakkola, Jouni Junnila, Thor Alvegård, Peter Reichardt. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol .2020 Aug 1;6(8):1241-1246. doi: 10.1001/jamaoncol.2020.2091.

Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma – the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.

Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jaeger, Magnus von Knebel Doeberitz. A Phase I/IIa Trial of a Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers. Clin Cancer Res. 2020 Jun 15; clincanres.3517.2019. doi: 10.1158/1078-0432.CCR-19-3517. Online ahead of print.

Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein. Ipilimumab or FOLFOX With Nivolumab and Trastuzumab in Previously Untreated HER2-positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma – The Randomized Phase 2 INTEGA Trial (AIO STO 0217). BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Jochen Schütte , Silke Cameron , Peter Hohenberger , Philipp J Jost , Salah-Eddin Al-Batran , Lars H Lindner , Sebastian Bauer , Eva Wardelmann , Bengt Nilsson , Raija Kallio , Panu Jaakkola , Jouni Junnila , Thor Alvegård , Peter Reichardt. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol. 2020 May 29;e202091. doi: 10.1001/jamaoncol.2020.2091. Online ahead of print.

Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Peter Thuss-Patience, Hans-Georg Kopp, Tobias Dechow,  Arndt Vogel, Kim Barbara Luley, Daniel Pink, Michael Stahl, Frank Kullmann, Holger Hebart, Jens Siveke, Matthias Egger, Nils Homann, Stephan Probst, Thorsten Oliver Goetze, Salah-Eddin Al-Batran. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/ platinum-containing regimen (RADPAC). Int J Cancer. 2020 Apr 27. doi: 10.1002/ijc.33025. Online ahead of print.

Salah-Eddin Al-Batran, Enno Moorahrend, Christoph Maintz, Thorsten O Goetze, Dirk Hempel, Peter Thuss-Patience, Vincent E Gaillard, Susanna Hegewisch-Becker. Clinical Practice Observation of Trastuzumab in Patients With Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Oncologist. 2020 Apr 20. doi: 10.1634/theoncologist.2020-0109. Online ahead of print.

E Van Cutsem, K Muro, D Cunningham, G Bodoky, A Sobrero, S Cascinu, J Ajani, S C Oh, S E Al-Batran , Z A Wainberg, S R Wijayawardana, S Melemed, D Ferry, R R Hozak, A Ohtsu, RAINBOW Investigators. Biomarker Analyses of Second-Line Ramucirumab in Patients With Advanced Gastric Cancer From RAINBOW, a Global, Randomized, Double-Blind, Phase 3 Study. Eur J Cancer. 2020 Mar;127:150-157. doi: 10.1016/j.ejca.2019.10.026. Epub 2020 Jan 31.

M Moehler, A Maderer, P C Thuss-Patience, B Brenner, J Meiler, T J Ettrich, R-D Hofheinz, S E Al-Batran, A Vogel, L Mueller, M P Lutz, F Lordick, M Alsina, K Borchert, R Greil, W Eisterer, A Schad, J Slotta-Huspenina, E Van Cutsem, S Lorenzen. Cisplatin and 5-fluorouracil With or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients With Non-Resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase III AIO/EORTC Trial (POWER). Ann Oncol. 2020 Feb;31(2):228-235. doi: 10.1016/j.annonc.2019.10.018. Epub 2019 Dec 16.

Van Cutsem E, Muro K, Cunningham D, Bodoky G, Sobrero A, Cascinu S, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A; RAINBOW Investigators. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 Mar;127:150-157. doi: 10.1016/j.ejca.2019.10.026. Epub 2020 Jan 31.

Goetze TO, Bechstein WO, Bankstahl US, Keck T, Königsrainer A, Lang SA, Pauligk C, Piso P, Vogel A, Al-Batran SE. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial. BMC Cancer. 2020 Feb 14;20(1):122. doi: 10.1186/s12885-020-6610-4.

Al-Batran SE, Pauligk C, Götze TO. Perioperative chemotherapy for gastric cancer in FLOT4 – Authors’ reply. Lancet. 2020 Jan 11;395(10218):e4. doi: 10.1016/S0140-6736(19)32516-4.

2019

Moehler M, Al-Batran SE, Andus T, Arends J, Arnold D, Baretton G, Bornschein J, Budach W, Daum S, Dietrich C, Ebert M, Fischbach W, Flentje M, Gockel I, Grenacher L, Haier J, Höcht S, Jakobs R, Jenssen C, Kade B, Kanzler S, Langhorst J, Link H, Lordick F, Lorenz D, Lorenzen S, Lutz M, Messmann H, Meyer HJ, Mönig S, Ott K, Quante M, Röcken C, Schlattmann P, Schmiegel WH, Schreyer A, Tannapfel A, Thuss-Patience P, Weimann A, Unverzagt S. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL. Z Gastroenterol. 2019 Dec;57(12):1517-1632. doi: 10.1055/a-1018-2516. Epub 2019 Dec 11. [Article in German]

Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, Hofheinz RD, Al-Batran SE, Vogel A, Mueller L, Lutz MP, Lordick F, Alsina M, Borchert K, Greil R, Eisterer W, Schad A, Slotta-Huspenina J, Van Cutsem E, Lorenzen S. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020 Feb;31(2):228-235. doi: 10.1016/j.annonc.2019.10.018. Epub 2019 Dec 16.

Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Aderka D, Tejpar S, Heinemann V. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019 Nov 1;30(11):1796-1803. doi: 10.1093/annonc/mdz387.

Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Sep;30(9):1487-1495. doi: 10.1093/annonc/mdz199. Epub 2019 Dec 12

Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O’Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019 Nov 14:JCO1902107. doi: 10.1200/JCO.19.02107. [Epub ahead of print]

Koch C, Reitz C, Schreckenbach T, Eichler K, Filmann N, Al-Batran SE, Götze T, Zeuzem S, Bechstein WO, Kraus T, Bojunga J, Düx M, Trojan J, Blumenstein I. Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma. PLoS One. 2019 Oct 22;14(10):e0223613. doi: 10.1371/journal.pone.0223613. eCollection 2019.

Lorenzen S, Stahl M, Hofheinz RD, Al-Batran SE, Lordick F. Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncol Res Treat. 2019 Oct 21:1-6. doi: 10.1159/000503428. [Epub ahead of print]

Fonkeu Y, Kraynyukova N, Hafner AS, Kochen L, Sartori F, Schuman EM, Tchumatchenko T. How mRNA Localization and Protein Synthesis Sites Influence Dendritic Protein Distribution and Dynamics. Neuron. 2019 Jul 23. pii: S0896-6273(19)30572-0. doi: 10.1016/j.neuron.2019.06.022. [Epub ahead of print]

Gaiser MR, Lorenzen S, Merx K, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Heeger S, Vlassak S, Koch W, Hofheinz RD.  Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score. Cancer Med. 2019 Aug;8(9):4169-4175. doi: 10.1002/cam4.2132. Epub 2019 Jun 14.

Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH.  Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective.  J Gastric Cancer. 2019 Jun;19(2):148-156. doi: 10.5230/jgc.2019.19.e19. Epub 2019 May 24

Türeci O; Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase 2a study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Jun 26. pii: mdz199. doi: 10.1093/annonc/mdz199. [Epub ahead of print]

Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. doi: 10.1177/1758835919850367. eCollection 2019

Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, Catenacci DV, Al-Batran SE, Posey JA. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? Am Soc Clin Oncol Educ Book. 2019 Jan;39:e88-e95. doi: 10.1200/EDBK_236827. Epub 2019 May 17.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 Apr 10. pii: S0140-6736(18)32557-1. doi: 10.1016/S0140-6736(18)32557-1. [Epub ahead of print]

Mockett BG, Guévremont D, Elder MK, Parfitt KD, Peppercorn K, Morrissey J, Singh A, Hintz TJ, Kochen L, Tom Dieck S, Schuman E, Tate WP, Williams JM, Abraham WC. Glutamate Receptor Trafficking and Protein Synthesis Mediate the Facilitation of LTP by Secreted Amyloid Precursor Protein-Alpha. J Neurosci. 2019 Apr 24;39(17):3188-3203. doi: 10.1523/JNEUROSCI.1826-18.2019. Epub 2019 Feb 25.

Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1.

Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.

2018

Roca-Ferrer J, Pujols L, Pérez-González M, Alobid I, Callejas B, Vicens-Artés S, Fuentes M, Valero A, Picado C,Castor D, Nguyen D, Mullol J. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy Asthma Clin Immunol. 2018 Dec 18;14:86. doi: 10.1186/s13223-018-0311-4. eCollection 2018.

Gaiser MR, Lorenzen S, Merx K, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Heeger S, Vlassak S, Koch W, Hofheinz RD. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: A post hoc analysis of the EVITA trial. Ann Oncol. 2018 Oct 11. doi: 10.1093/annonc/mdy451. [Epub ahead of print].

Mueller DW, Goetze TO, Eickhoff R, Reichart A, Al-Batran SE. The “INSIGHT” trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities. Journal of Clinical Oncology 2018 36:15_suppl, TPS3129-TPS3129

Amato G, Romano G, Puleio R, Agrusa A, Goetze T, Gulotta E, Gordini L, Erdas E, Calò P. Neomyogenesis in 3D Dynamic Responsive Prosthesis for Inguinal Hernia Repair. Artif Organs. 2018 Oct 14

Gutt C, Jenssen C, Barreiros AP, Götze TO, Stokes CS, Jansen PL, Neubrand M, Lammert F; für die Teilnehmer der Konsensuskonferenz; Deutsche Gesellschaft für Innere Medizin e.V. (DGIM); Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH); Schweizer Gesellschaft für Gastroenterologie (SGH); Gesellschaft für Humangenetik (GfH); Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Chirurgie (DGCH); Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG; beratende Funktion ohne Stimmrecht); Deutsche Arbeitsgemeinschaft zum Studium der Leber (GASL); Deutsche Röntgengesellschaft (DRG); Deutsche Leberhilfe e. V. [Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones. German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) – AWMF Registry 021/008]. Z Gastroenterol. 2018 Aug;56(8):912-966

Lu Y, Rafiq A, Zhang Z, Aslani F, Fijak M, Lei T, Wang M, Kumar S, Klug J, Bergmann M, Chakraborty T, Meinhardt A, Bhushan S. Uropathogenic Escherichia coli virulence factor hemolysin A causes programmed cell necrosis by altering mitochondrial dynamics. FASEB J. 2018 Aug;32(8):4107-4120. doi: 10.1096/fj.201700768R

Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, Tannapfel A, Arnold D. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. Eur J Cancer. 2018 Sep;101:105-113. doi: 10.1016/j.ejca.2018.06.015. Epub 2018 Jul 20.

Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Jul 24. doi: 10.1093/annonc/mdy264. [Epub ahead of print]

Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018 Jul 10. doi: 10.1038/s41416-018-0150-6. [Epub ahead of print]

Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A, Al-Batran SE. Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev. 2018 Jun 18;69:90-100. doi: 10.1016/j.ctrv.2018.06.012. [Epub ahead of print]

Goetze TO, Al-Batran SE, Pabst U, Reymond M, Tempfer C, Bechstein WO, Bankstahl U, Gockel I, Königsrainer A, Kraus T, Mönig SP, Rau B, Schwarzbach M, Piso P. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO.  Pleura Peritoneum. 2018 Jun 8;3(2):20180113. doi: 10.1515/pp-2018-0113. eCollection 2018 Jun 1.

Goetze TO, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg. 2018 Jun;70(2):173-179. doi: 10.1007/s13304-018-0539-z. Epub 2018 Jun 26.

Dörrbaum AR, Kochen L, Langer JD, Schuman EM. Local and global influences on protein turnover in neurons and glia. Elife. 2018 Jun 19;7. pii: e34202. doi: 10.7554/eLife.34202.

Nagel M, Schulz J, Maderer A, Goepfert K, Gehrke N, Thomaidis T, Thuss-Patience PC, Al-Batran SE, Hegewisch-Becker S, Grimminger P, Galle PR, Möhler M, Schattenberg JM. Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial. Tumour Biol. 2018 Mar;40(3):1010428318764007. doi: 10.1177/1010428318764007.

Hofheinz RD, Lorenzen S, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Tetyusheva M, Heeger S, Vlassak S, Merx K. EVITA – A double-blind, vehicle controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol. 2018 Jan 18. doi: 10.1093/annonc/mdy015. [Epub ahead of print]

Hammerer P, Al-Batran SE, Windemuth-Kieselbach C, Keller M, Hofheinz RD. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study. World J Urol. 2018 Jan 5. doi: 10.1007/s00345-017-2138-x. [Epub ahead of print]

Deckmann K, Rafiq A, Erdmann C, Illig C, Durschnabel M, Wess J, Weidner W, Bschleipfer T, Kummer W. Muscarinic receptors 2 and 5 regulate bitter response of urethral brush cells via negative feedback. FASEB J. 2018 Jun;32(6):2903-2910. doi: 10.1096/fj.201700582R. Epub 2018 Jan 17

Falkenstein TA, Götze TO, Ouaissi M, Tempfer CB, Giger-Pabst U, Demtröder C. First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer. Anticancer Res. 2018 Jan;38(1):373-378.